Popoola et al., 2024 - Google Patents
Lung-specific mRNA delivery enabled by sulfonium lipid nanoparticlesPopoola et al., 2024
View HTML- Document ID
- 4904018614270076990
- Author
- Popoola D
- Cao Z
- Men Y
- Li X
- Viapiano M
- Wilkens S
- Luo J
- Teng Y
- Meng Q
- Li Y
- Publication year
- Publication venue
- Nano letters
External Links
Snippet
Among various mRNA carrier systems, lipid nanoparticles (LNPs) stand out as the most clinically advanced. While current clinical trials of mRNA/LNP therapeutics mainly address liver diseases, the potential of mRNA therapy extends far beyond─ yet to be unraveled. To …
- 108020004999 messenger RNA 0 title abstract description 456
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using micro-encapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eygeris et al. | Chemistry of lipid nanoparticles for RNA delivery | |
| Torres-Vanegas et al. | Delivery systems for nucleic acids and proteins: Barriers, cell capture pathways and nanocarriers | |
| Dilliard et al. | Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs | |
| Kazemian et al. | Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components | |
| Lokugamage et al. | Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs | |
| Chen et al. | Modular design of biodegradable ionizable lipids for improved mRNA delivery and precise cancer metastasis delineation in vivo | |
| Cao et al. | Helper-polymer based five-element nanoparticles (FNPs) for lung-specific mRNA delivery with long-term stability after lyophilization | |
| Johnson et al. | Lipid nanoparticle (LNP) chemistry can endow unique in vivo RNA delivery fates within the liver that alter therapeutic outcomes in a cancer model | |
| Aliakbarinodehi et al. | Interaction kinetics of individual mRNA-containing lipid nanoparticles with an endosomal membrane mimic: dependence on pH, protein corona formation, and lipoprotein depletion | |
| Kulkarni et al. | On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA | |
| Cai et al. | Bioreducible fluorinated peptide dendrimers capable of circumventing various physiological barriers for highly efficient and safe gene delivery | |
| Sinclair et al. | Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing | |
| Sahel et al. | CRISPR/Cas9 genome editing for tissue‐specific in vivo targeting: nanomaterials and translational perspective | |
| Chen et al. | Amphiphilic dendrimer vectors for RNA delivery: State-of-the-art and future perspective | |
| Thai et al. | Kidney-targeted cytosolic delivery of siRNA using a small-sized mirror DNA tetrahedron for enhanced potency | |
| Leung et al. | Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems | |
| Popoola et al. | Lung-specific mRNA delivery enabled by sulfonium lipid nanoparticles | |
| Merkel et al. | Nonviral siRNA delivery to the lung: Investigation of PEG− PEI polyplexes and their in vivo performance | |
| Whitehead et al. | In vitro–in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery | |
| Reinhart et al. | Investigations into mRNA lipid nanoparticles shelf-life stability under nonfrozen conditions | |
| Gindy et al. | Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery | |
| Johnson et al. | Fluorocarbon modified low-molecular-weight polyethylenimine for siRNA delivery | |
| Rhym et al. | Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art | |
| Golubovic et al. | Bioinspired lipid nanocarriers for RNA delivery | |
| Kim et al. | Microfluidic platform enables shearless aerosolization of lipid nanoparticles for mRNA inhalation |